





## Complete Genome Sequence of *Neisseria gonorrhoeae* Multilocus Sequence Type ST7363 Isolated from Thailand

**Microbiology**<sup>®</sup>

**Resource Announcements** 

<sup>®</sup> Thitima Cherdtrakulkiat,<sup>a,b,c</sup> <sup>®</sup> Thidathip Wongsurawat,<sup>d,e</sup> Piroon Jenjaroenpun,<sup>d,e</sup> Sawannee Sutheeworapong,<sup>f</sup> Wanna Leelawiwat,<sup>a,b</sup> Joseph V. Woodring,<sup>a,b</sup> Eileen F. Dunne,<sup>a,b</sup> John R. Papp,<sup>g</sup> Somporn Srifuengfung,<sup>h</sup> <sup>®</sup> Chanwit Tribuddharat<sup>i</sup>

<sup>a</sup>Division of HIV/AIDS Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
 <sup>b</sup>Thailand Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand
 <sup>c</sup>Molecular Medicine Graduate Program, Faculty of Science, Mahidol University, Bangkok, Thailand
 <sup>d</sup>Division of Bioinformatics and Data Management for Research, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
 <sup>e</sup>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
 <sup>e</sup>Plot Plant Development and Training Institute, King Mongkut's University of Technology Thonburi, Bangkok, Thailand
 <sup>g</sup>Division of Sexually Transmitted Disease Prevention, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
 <sup>h</sup>Faculty of Pharmacy, Siam University, Bangkok, Thailand
 <sup>i</sup>Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

**ABSTRACT** A *Neisseria gonorrhoeae* multilocus sequence type (MLST) ST7363 strain was isolated from a patient at the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, in 2010 and completely sequenced. This strain is susceptible to ceftriaxone and cefixime. A complete circular chromosome and circular plasmids were assembled from combined Oxford Nanopore Technologies (ONT) and Illumina sequencing.

**G**onorrhea, caused by *Neisseria gonorrhoeae*, is among the most common sexually transmitted infections worldwide (1). Antimicrobial-resistant (AMR) *N. gonorrhoeae* is considered a high priority by the World Health Organization and an urgent threat by the U.S. Centers for Disease Control and Prevention (CDC) (2–5). Genomic analysis has been used to address the evolution and transmission of ceftriaxone-resistant genes (6, 7). We report here the complete genome sequence of a multilocus sequence type (MLST) ST7363 *N. gonorrhoeae* strain. This study was approved by the institutional review boards (IRBs) of the Faculty of Medicine Siriraj Hospital (certificate of approval number Si479/2015). The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), CDC, also reviewed and approved this study protocol and determined it to be research that did not involve identifiable human subjects, using unlinked or anonymous data or specimens, and therefore, CDC IRB approval was not required.

Based on our published data (8, 9), we selected the MLST ST7363 isolate from all frozen *N. gonorrhoeae* stock that was resistant to fluoroquinolone, penicillin, and tetracycline by disk diffusion (10) and harbored the  $bla_{\text{TEM}}$  gene for  $\beta$ -lactam resistance. The frozen isolates were cultured on chocolate agar in 5% CO<sub>2</sub> at 35°C and confirmed using Gram staining, oxidase and superoxol assays, and the API-NH (bioMérieux) biochemical test kit. An Etest (bioMérieux) was used to determine the MICs for ceftriaxone, cefixime, azithromycin, tetracycline, and gentamicin.

Genomic DNA was extracted from the colonies scraped from a chocolate agar plate using the Gentra Puregene yeast/bacteria kit (Qiagen). The extracted DNA was used for the Oxford Nanopore Technologies (ONT) and Illumina sequencing. Citation Cherdtrakulkiat T, Wongsurawat T, Jenjaroenpun P, Sutheeworapong S, Leelawiwat W, Woodring JV, Dunne EF, Papp JR, Srifuengfung S, Tribuddharat C. 2021. Complete genome sequence of *Neisseria gonorrhoeae* multilocus sequence type ST7363 isolated from Thailand. Microbiol Resour Announc 10:e00573-21. https://doi.org/10 .1128/MRA.00573-21.

**Editor** Julie C. Dunning Hotopp, University of Maryland School of Medicine

This is a work of the U.S. Government and is not subject to copyright protection in the United States. Foreign copyrights may apply. Address correspondence to Chanwit

Tribuddharat, chanwit.tri@mahidol.ac.th. Received 20 July 2021

Accepted 20 September 2021 Published 14 October 2021

GenBank accession		Total length	Sequenc (×)	ing depth	GC content	No. of
no.	Type of contig	(bp)	ONT	Illumina	(%)	ORFs <sup>a</sup>
CP045707.1	Circular chromosome	2,166,131	143	559	52.6	2,298
CP045708.1	Conjugative plasmid	42,907	658	1,912	47.6	51
CP045709.1	bla <sub>TEM</sub> plasmid	5,154	34,644	10,363	38.4	5
CP045710.1	Cryptic plasmid	4,207	32,101	11,384	51.6	10

**TABLE 1** Assembly metrics and accession numbers of an MLST ST7363 Neisseria gonorrhoeae

 strain isolated from clinical specimens, Siriraj Hospital, Bangkok, Thailand, 2010

<sup>a</sup>ORFs, open reading frames.

The ONT library preparation followed the rapid barcoding sequencing protocol (SQK-RBK004; ONT), and sequencing was performed using an R9.4.1/FLO-MIN106 flow cell on a MinION device. We used Guppy v3.0.3 for base calling and demultiplexing of the reads. Quality control of the ONT reads followed the workflow from Jenjaroenpun et al. (11). The ONT adapters were trimmed using Porechop v0.2.3 (https://github.com/rrwick/Porechop). Reads with a mean quality score of 8 and a minimum read length of 1,000 bases were retained using NanoFilt v2.5.0 (12) for *de novo* assembly.

The Illumina library was prepared using a TruSeq DNA PCR-free library to generate 100-bp paired-end reads using the Illumina HiSeq platform. Quality control of the reads was performed using Fastp v0.19.5 (13). Hybrid assembly (ONT and Illumina data) was performed using Unicycler v0.4.4 (14) for genome error correction, circularization, and rotation. The genome sequence quality was determined using QUAST v5.0.2 (15) and submitted to the NCBI Prokaryotic Genome Annotation Pipeline v4.9 for genome annotation (16). Default parameters were used for all software.

The genome size was 2,218,399 bp. The assembly statistics and GenBank accession numbers are provided in Table 1. The  $N_{50}$  value/total read length (bp) of the ONT and Illumina reads were 4,248/182,670 and 100/13,878,684, respectively. A complete circular chromosome and plasmids, constructed using Unicycler software to check for overlapping sequences at the contig ends, demonstrated that the ST7363 isolate contained 3 circular plasmids, namely, conjugative,  $bla_{TEM}$ , and cryptic plasmids. *In silico* analysis confirmed sequence types of  $bla_{TEM-135}$ , MLST ST7363, and *N. gonorrhoeae* multiantigen sequence typing (NG-MAST) ST5225 (*por90/tbpB1106*). A novel sequence type, ST2209 (*penA2.002, mtrR19, porB11, ponA100, gyrA1, parC18,* and *23s100*), was uploaded to the NG-STAR database (17). The AMR determinants were defined using PubMLST (http://www.pubmlst.org/neisseria) (18). Type II nonmosaic *penA* possessed F504L, A511V, and A517G mutations, while *gyrA* had S91F and D95G mutations and *parC* had a D86N mutation. In contrast to the reported cephalosporin-resistant ST7363-*penA10.001/37.001/64.001*, our MLST ST7363-*penA2.002* was susceptible (Fig. 1) (19–21).

**Data availability.** The genome sequence has been submitted to GenBank under BioProject accession number PRJNA609415 and BioSample accession number SAMN13151449. The Illumina and ONT raw reads have been deposited in the SRA database under accession numbers SRR10362752 and SRR10388020.

## Microbiology Resource Announcement

	10	20	30	40	50	60	70	80	90	100
LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001										
	MLIKSEYKPRMLPKE									
WHO_X_JP_ 2009_penA37.001										
WHO_Z AU_2013_penA64.001	••••••		•••••	• • • • • • • • • •	•••••	• • • • • • • • • • •	• • • • • • • • • •	• • • • • • • • •	•••••	• • • •
					45.0		4.5.4			
	110	120	130	140	150	160	170	180	190	200
LM306_UK_1988_penA WT FA1090_US_1980_penA1.002 NG250_TH_2010_penA2.002 WHO K_JP_2003_penA10.001	DMKEMPSAAOLERLSE									
	DMKEMPSAAQLERLSE									
	Е									
WHO W HK 2007 penA10.001	E									
WHO X JP 2009 penA37.001	E									
WHO Z AU 2013 penA64.001	E									
MIC_2 AC_2015_peract.cor										••••
	210	220	230	240	250	260	270	280	290	300
LM306 UK 1988 penA WT	YGEDGAEVVLRDROGN	IVDSLDSPR	NKAPONGKDI	ILSLDORIOT	LAYEELNKAV	EYHOAKAGTV	VLDARTGEI	LALANTPAY	PNRPGRADSE	ORRNR
FA1090 US 1980 penA1.002										
NG250 TH 2010 penA2.002										
WHO K JP 2003 penA10.001	HAGE E							vB	<b>K</b> Q	
WHO_W_HK_2007_penA10.001	HAGEE.									
WHO_X_JP_ 2009_penA37.001	HAGE									
WHO_Z_AU_2013_penA64.001	HAGEE.		· · · · · · · · · · ·	• • • • • • • • • • •		•••••			•••••••	
	\$10	320	330	340	350	360	370	380	390	400
	· · · · · · · · · · · · · · · · · · ·									
LM306_UK_1988_penA WT	AVTDMIEPGSAIKPFV	IAKALDAGK	TDLNERLNTÇ	PYKIGPSPVR	D~THVYPSLD	VRGIMQKSSN	/GTSKLSARF	AEEMYDFYF	ELGIGVRMHS	GFPGE
FA1090_US_1980_penA1.002	AVTDMIEPGSAIKPFV	IAKALDAGK	TDLNERLNTÇ	PYKIGPSPVR	D~THVYPSLD	VRGIMQKSSN	/GTSKLSARF	GAEEMYDFYF	ELGIGVRMHS	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002	AVTDMIEPGSAIKPF	IAKALDAGK	TDLNERLNTÇ	PYKIGPSPVR		VRGIMQKSSN	/GTSKLSARF(	GAEEMYDFYF	IELGIGVRMHS	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K_JP_2003 penA10.001	AVTDMIEPGSAIKPFT	/IAKALDAGK	TDLNERLNTÇ	PYKIGPSPVR	D~THVYPSLD .D	VRGIMQKSSN	/GTSKLSARF(	GAEEMYDFYF	ELGIGVRMHSC	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001	AVTDMIEPGSAIKPFV	IAKALDAGK	TDLNERLNTÇ V.ATDTF.I V.ATDTF.I	PYKIGPSPVR	D~THVYPSLD .D .DT T	VRGIMQKSSN	/GTSKLSARF(	GAEEMYDFYF	ELGIGVRMHSC	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K_JP_2003 penA10.001 WHO W_HK_2007 penA10.001 WHO X_JP_ 2009 penA37.001	AVTDMIEPGSAIKPFV	IAKALDAGK	TDLNERLNTC V.ATDTFI V.ATDTFI V.TTDTFI	PYKIGPSPVR	D~THVYPSLD D	VRGIMQKSSN	/GTSKLSARF(	GAEEMYDFYF	D.V. D.V.	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001	AVTDMIEPGSAIKPFV	IAKALDAGK	TDLNERLNTC V.ATDTFI V.ATDTFI V.TTDTFI	PYKIGPSPVR	D~THVYPSLD D	VRGIMQKSSN	/GTSKLSARF(	GAEEMYDFYF	ELGIGVRMHSC	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K_JP_2003 penA10.001 WHO W_HK_2007 penA10.001 WHO X_JP_ 2009 penA37.001	AVTDMIEPGSAIKPFV	IAKALDAGK	TDLNERLNTC V.ATDTFI V.ATDTFI V.TTDTFI	PYKIGPSPVR	D~THVYPSLD D	VRGIMQKSSN	/GTSKLSARF(	GAEEMYDFYF	D.V. D.V.	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K_JP_2003 penA10.001 WHO W_HK_2007 penA10.001 WHO X_JP_ 2009 penA37.001	AVTDMIEPGSAIKPFV 	YIAKALDAGK	V.ATDTF.I V.ATDTF.I V.TTDTF.I V.TTDTF.I V.TTDTF.I	2PYKIGPSPVR SAT.Q SAT.Q AT.Q 440	D~THVYPSLD .D .D T T T T 450	460	/GTSKLSARF( 	3AEEMYDFYF 5AEEMYDFYF 5PK 5PK 5PK 6PK 680	IELGIGVRMHS( D. V D. V D. V D. V D. V 490	GFPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K_JP_2003 penA10.001 WHO W HK 2007 penA10.001 WHO X_JP_ 2009 penA37.001 WHO Z_AU_2013 penA64.001	AVTDMIEPGSAIKPF( 	YIAKALDAGK	V.ATDTF.I V.ATDTF.I V.ATDTF.I V.TTDTF.I V.TTDTF.I 430	2007KIGPSPVR	D~THVYPSLD .D. 	460	7GTSKLSARF( 	480	ELGIGVRMHS( D.V. D.V. D.V. D.V. D.V. D.V.	3FPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT	AVTDMIEPGSAIKPFV 	11KALDAGK	TDLNERLNTÇ V.ATDTF.I V.ATDTF.I V.TTDTF.I V.PTDTF.I 430	2007 200 200	D~THVYPSLD .D. .D. T. T. T. T. 450 	460 APQGKRIFKE	470	3A EEMYDFYF           5A EEMYDFYF           FPK.	IELGIGVRMHS0           D. V.           D. V.	3FPGE
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K_JP_2003 penA10.001 WHO W HK 2007 penA10.001 WHO X_JP_ 2009 penA37.001 WHO Z_AU_2013 penA64.001	AVTDMIEPGSAIKPFV 	IIAKALDAGK          S.	V.ATDTF.I V.ATDTF.I V.TDTF.I V.TDTF.I V.PTDTF.I 430	PYKI GPSPVR SAT.Q SAT.Q AT.Q 440 AT.Q	D ~ THVYPSLD .D	460 APQGKRIFKE	7GT SKLSARF( 	3A EEMYDFYF           CPK.           CPK.           CPK.           CPK.           CPK.           CPK.           VEVE           480           J.SVTE           JSVTE	190 191 191 191 191 191 191 191	500 53 <b>FPGE</b>
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002	AVTDMIEPGSAIKPFV 	IAKALDAGK	V.ATDTF.I V.ATDTF.I V.TDDTF.I 430		D-THVYPSLD D. D. T. T. T. 450 	460 APQGKRIFKE:	7GTSKLSARF( 	TPK. TPK. TPK. TPK. 480 JSVTEPGGTO A	D. V. D. V. D. V. D. V. D. V. D. V. D. V. STAGAVDGFDV(	500 3 <b>FPGE</b> 500 1 <b>3AKTG</b>
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001	AVTDMIEPGSAIKPF( 	IAKALDAGK	V.ATDTF.I V.ATDTF.I V.TTDTF.I V.TTDTF.I QLSLLQLARA		D-THVYPSLD D. .D. T. T. 450 	460 APQGKRIFKE:	ATTORNESS AND	ARC ACCEPT	190 191 191 191 191 191 191 191	500 53 <b>F</b> PG <b>E</b>
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO W JP 2009 penA37.001	AVTDMI EPGSAIKPFV 	IAKALDAGK	V.ATDTF.I V.ATDTF.I V.TTDTF.I V.TTDTF.I 430		D-THVYPSLD D.T.T. 	460 460 APQGKRIFKE 	/GTSKLSARF( 	480 480 480 480 480 480 480 480	10. V. D. V. D. V. D. V. D. V. D. V. D. V. TAGAVDGFDVC	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001	AVTDMIEPGSAIKPF( 	IAKALDAGK	V.ATDTF.I V.ATDTF.I V.TTDTF.I V.TTDTF.I 430		D-THVYPSLD D.T.T. 	460 460 APQGKRIFKE 	/GTSKLSARF( 	480 480 480 480 480 480 480 480	10. V. D. V. D. V. D. V. D. V. D. V. D. V. TAGAVDGFDVC	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO W JP 2009 penA37.001	AVTDMIEPGSAIKPF 	IAKALDAGK S.S.S. S.S. 420 JATMSFGYGL	V.ATDTF.I V.ATDTF.I V.TTDTF.I V.TTDTF.I QLSLLQLARA		D-THVYPSLD D.THVYPSLD D.T.T. T. T. 450 	460 APQGKRIFKE: KVI.A KVI.A KVI.A	ATO KK. E. KK. E. KK. E. KK. E. KK. E.	480 480 480 480 480 480 480 480	10. V. D. V. D. V. D. V. D. V. D. V. D. V. TAGAVDGFDVC	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO W JP 2009 penA37.001	AVTDMI EPGSAIKPFV 	11 AKALDAGK 	V.ATDTF.I V.ATDTF.I V.ATDTF.I V.TTDTF.I 430 J.J.J QLSLLQLAR2 530		D-THVYPSLD D.T.T. D.T.T. T. T. 450 LPLSFEKQAV 	460 460 	470 	3A EEMYDFYF           FPK           FPK           PFK           7SVTEPGGGG	10. V. D. V. D. V. D. V. D. V. D. V. D. V. TAGAVDGFDVC	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001	AVTDMIEPGSAIKPFX 	114KALDAGK	V.ATDTF.I V.ATDTF.I V.TDDTF.I V.TDDTF.I QLSLLQLARA		D-THVYPSLD D. 	460 460 	470 KK. E. KK. E. KK. E. KK. E. KK. E. KK. E. KK. E. KK. E. KK. E.	3A EEMYDFYF           FPK.           FPK.           FPK.           FPK.           I           480           I           480           I           480           I           7SVTEPGGT3           A           A           S80	D. V. D. V. D. V. D. V. D. V. D. V. D. V. J. V. J. V. J	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT	AVTDMI EPGSAIKPFX 	1AKALDAGK	V.ATDTF.I V.ATDTF.I V.ATDTF.I V.TTDTF.I QLSLLQLARA 530		D-THVYPSLD D.THVYPSLD D.T.T. T. T. 450 	460 460 		3A EEMYDFYH           FPK.           FPK.           FPK.           FPK.           FPK.           I           J.SVTEPGGT           A           A           A           A           Source PGGT           A           A           A           Source PGGT           A           A           Source PGGT           A           A           Source PGGT           Source PGGT           Source PGGT           A           Source PGGT           Source PGGT <th>10. V</th> <th>500 500</th>	10. V	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002	AVTDMI EPGSAIKPFV 	12441DAGK	V.ATDTFI V.ATDTFI V.ATDTFI V.TTDTFI QLSLLQLARA 530		D-THVYPSLD D.THVYPSLD D.T.T. T. T. 450 	460 460 		480 1	1	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA10.001 WHO K JP 2003 penA10.001 WHO X JP 2003 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002	AVTDMI EPGSAIKPFV 	11AKALDAGK	TDLNERLNTÇ V.ATDTF.I V.ATDTF.I V.TTDTF.I 430 QLSLLQLARA 530		D-THVYPSLD D. .D. T. T. 	460 460 	470 	3A EEMYDFYF           FPK.           FPK. <th>1</th> <th>500 500</th>	1	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 WHO K JP 2003 penA10.001 WHO X JP 2009 penA37.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001	AVTDMI EPGSAIKPFV 	1AKALDAGK	V.ATDTF.I V.ATDTF.I V.TTDTF.I V.TTDTF.I QLSLLQLARA		D-THVYPSLD D.THVYPSLD D.T.T. DT. T. T. 450 	460 460 		3A EEMYDFYH           FPK.           FPK.           FPK.           FPK.           1           JSVTEPGGT           A.           A.           S80           I           A.           S80           I           A.           S80           I           I           S80           I           I           S80           I           X           X	1	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA1.002 NG250 TH 2010 penA1.002 NG250 TH 2010 penA1.002 NHO K JP 2003 penA10.001	AVTDMI EPGSAIKPFV 	11 AKALDAGK S. 	V.ATDTFI V.ATDTFI V.TTDTFI 430 		D-THVYPSLD D.THVYPSLD D.T.T. T. T. 450  LPLSFEKQAV 	460 460 		3A EEMYDFYF           FPK.           FPK.           FPK.           FPK.           FPK.           FPK.           State           A.           A.           A.           State           State     <	1	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO X JP 2009 penA37.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA10.001 WHO K JP 2003 penA10.001 WHO X JP 2003 penA10.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA1.001 WHO K JP 2003 penA1.001 WHO K JP 2003 penA1.001 WHO K JP 2003 penA1.001	AVTDMI EPGSAIKPFV 	11 AKALDAGK 	TDLNERLNTÇ V.ATDTF.I V.ATDTF.I V.TTDTF.I 430 QLSLLQLAR2 530		D-THVYPSLD D.T.T.Y. D.T.T.T. D.T.T.T. D.T.T.T. D.T.T.T.T	460 460 	/GTSKLSARF( 	3A EEMYDFYF         FPK.         FPK.         FPK.         FPK.         FPK.         FPK.         FPK.         FPK.         Solution         A.         Solution         A.         Solution	1	500 500
FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO W HK 2007 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA10.001 WHO X JP 2009 penA37.001 WHO Z AU 2013 penA64.001 LM306 UK 1988 penA WT FA1090 US 1980 penA1.002 NG250 TH 2010 penA2.002 WHO K JP 2003 penA1.002 NG250 TH 2010 penA1.002 NG250 TH 2010 penA1.002 NHO K JP 2003 penA10.001	AVTDMI EPGSAIKPFV 	11 AKALDAGK 	TDLNERLNTÇ V.ATDTF.I V.ATDTF.I V.TTDTF.I 430 QLSLLQLAR2 530		D-THVYPSLD D.T.T.Y. D.T.T.T. D.T.T.T. D.T.T.T. D.T.T.T.T	460 460 	/GTSKLSARF( 	3A EEMYDFYF         FPK.         FPK.         FPK.         FPK.         FPK.         FPK.         FPK.         FPK.         Solution         A.         Solution         A.         Solution	1	500 500

FIG 1 Multiple sequence alignment of penicillin-binding protein 2 (PBP2) coding sequences of the penA genes of ST7363 Neisseria gonorrhoeae from Thailand (NG250) with penA2.002 (this study), compared with LM306 wild-type penA, the reference strain FA1090 (penA1.002), and four WHO reference strains, including WHO K (penA37.001), WHO W (penA10.001), WHO X (penA37.001), and WHO Z (penA64.001). All four of these WHO strains belong to ST7363 and cephalosporin-resistant Neisseria gonorrhoeae strains. The sequence titles of the strains are listed on the left in the following format: strain name\_country source\_year of isolation\_penA type. The ruler with numbers on top of the sequences indicates the amino acid positions. The dot plots are a visual representation of the similarities between each sequence compared with the wild type in the first row. The A311V, I312M, and T483S mutations, which were previously reported in ceftriaxone-resistant strains and not found in our Thai susceptible strain, are indicated by the red rectangles. The MICs of strain NG250 for ceftriaxone and cefixime were 0.004 and 0.016  $\mu$ g/ml, respectively.

## **ACKNOWLEDGMENTS**

This work was supported by the Siriraj Foundation for Graduate Students (D003474) and the Division of HIV/AIDS Prevention, NCHHSTP, CDC.

We thank Andrew Hickey for technical advice and support.

Disclaimers: The findings and conclusions of the manuscript are those of the authors and do not necessarily represent the official views of the CDC. Use of trade names is for identification only and does not imply endorsement by the CDC or by the U.S. Department of Health and Human Services.

## REFERENCES

1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M. 2015. Global estimates of the prevalence and incidence of four curable sexually

- Unemo M, Shafer WM. 2014. Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future. Clin Microbiol Rev 27:587–613. https://doi.org/10.1128/CMR.00010-14.
- Cole MJ, Spiteri G, Jacobsson S, Woodford N, Tripodo F, Amato-Gauci AJ, Unemo M, Euro-GASP network. 2017. Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in *Neisseria* gonorrhoeae in 24 European countries, 2015. BMC Infect Dis 17:617. https://doi.org/10.1186/s12879-017-2707-z.
- WHO. 2014. Antimicrobial resistance: global report on surveillance. WHO, Geneva, Switzerland.
- CDC. 2019. Antibiotic resistance threats in the United States, 2019. U.S. Department of Health and Human Services, CDC. https://www.cdc.gov/ drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
- Unemo M, Golparian D, Eyre DW. 2019 Antimicrobial resistance in *Neisseria* gonorrhoeae and treatment of gonorrhea, p 37–58. *In* Christodoulides M (ed), *Neisseria gonorrhoeae*: methods and protocols, vol 1997. Springer, New York, NY.
- De Silva D, Peters J, Cole K, Cole MJ, Cresswell F, Dean G, Dave J, Thomas DR, Foster K, Waldram A, Wilson DJ, Didelot X, Grad YH, Crook DW, Peto TEA, Walker AS, Paul J, Eyre DW. 2016. Whole-genome sequencing to determine *Neisseria gonorrhoeae* transmission: an observational study. Lancet Infect Dis 16:1295–1303. https://doi.org/10.1016/S1473-3099(16)30157-8.
- Tribuddharat C, Pongpech P, Charoenwatanachokchai A, Lokpichart S, Srifuengfung S, Sonprasert S. 2017. Gonococcal antimicrobial susceptibility and prevalence of *bla*<sub>TEM-13</sub> and *bla*<sub>TEM-135</sub> genes in *Neisseria gonorrhoeae* isolates from Thailand. Jpn J Infect Dis 70:213–215. https://doi.org/10 .7883/yoken.JJID.2016.209.
- Cherdtrakulkiat T, Wongsurawat T, Jenjaroenpun P, Sutheeworapong S, Leelawiwat W, Hickey AC, Dunne EF, Raengsakulrach B, Tribuddharat C. 2020. Complete genome sequences of three *Neisseria gonorrhoeae* isolates from Thailand with multidrug resistance and multilocus sequence type 1903. Microbiol Resour Announc 9:e00198-20. https://doi.org/10.1128/MRA.00198-20.
- Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100, 29th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- 11. Jenjaroenpun P, Wongsurawat T, Udaondo Z, Anderson C, Lopez J, Mohan M, Tytarenko R, Walker B, Nookaew I, Ussery D, Kothari A, Jun S-R. 2020. Complete genome sequences of four isolates of vancomycin-resistant *Enterococcus faecium* with the *vanA* gene and two daptomycin resistance mutations, obtained from two inpatients with prolonged bacteremia. Microbiol Resour Announc 9: e01380-19. https://doi.org/10.1128/MRA.01380-19.

- De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. 2018. NanoPack: visualizing and processing long-read sequencing data. Bioinformatics 34:2666–2669. https://doi.org/10.1093/bioinformatics/bty149.
- Chen S, Zhou Y, Chen Y, Gu J. 2018. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34:i884–i890. https://doi.org/10.1093/bioinformatics/ bty560.
- 14. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595. https://doi.org/10.1371/journal.pcbi.1005595.
- Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUAST: quality assessment tool for genome assemblies. Bioinformatics 29:1072–1075. https:// doi.org/10.1093/bioinformatics/btt086.
- Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Nawrocki EP, Zaslavsky L, Lomsadze A, Pruitt KD, Borodovsky M, Ostell J. 2016. NCBI Prokaryotic Genome Annotation Pipeline. Nucleic Acids Res 44:6614–6624. https://doi.org/ 10.1093/nar/gkw569.
- Demczuk W, Sidhu S, Unemo M, Whiley DM, Allen VG, Dillon JR, Cole M, Seah C, Trembizki E, Trees DL, Kersh EN, Abrams AJ, de Vries HJC, van Dam AP, Medina I, Bharat A, Mulvey MR, Van Domselaar G, Martin I. 2017. *Neisseria gonorrhoeae* sequence typing for antimicrobial resistance, a novel antimicrobial resistance multilocus typing scheme for tracking global dissemination of *N. gonorrhoeae* strains. J Clin Microbiol 55: 1454–1468. https://doi.org/10.1128/JCM.00100-17.
- Jolley KA, Bray JE, Maiden MCJ. 2018. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res 3:124. https://doi.org/10.12688/wellcomeopenres.14826.1.
- Nakayama S-I, Shimuta K, Furubayashi K-I, Kawahata T, Unemo M, Ohnishi M. 2016. New ceftriaxone- and multidrug-resistant *Neisseria gonorrhoeae* strain with a novel mosaic *penA* gene isolated in Japan. Antimicrob Agents Chemother 60:4339–4341. https://doi.org/10.1128/AAC.00504-16.
- Lahra MM, Martin I, Demczuk W, Jennison AV, Lee K-I, Nakayama S-I, Lefebvre B, Longtin J, Ward A, Mulvey MR, Wi T, Ohnishi M, Whiley D. 2018. Cooperative recognition of internationally disseminated ceftriaxone-resistant *Neisseria gonorrhoeae* strain. Emerg Infect Dis 24:735–740. https://doi.org/10.3201/eid2404.171873.
- 21. Yahara K, Ma KC, Mortimer TD, Shimuta K, Nakayama S-I, Hirabayashi A, Suzuki M, Jinnai M, Ohya H, Kuroki T, Watanabe Y, Yasuda M, Deguchi T, Eldholm V, Harrison OB, Maiden MCJ, Grad YH, Ohnishi M. 2021. Emergence and evolution of antimicrobial resistance genes and mutations in *Neisseria gonorrhoeae*. Genome Med 13:51. https://doi.org/10.1186/s13073-021-00860-8.